王玉强

· 学院:药学院

· 性别:

· 籍贯:山东

· 职称:教授博导,硕导

· 学历:研究生

· 邮箱:yuqiangwang2001@yahoo.com

· 学院:药学院

· 性别:

· 籍贯:山东

· 职称:教授博导,硕导

· 学历:研究生

· 邮箱:yuqiangwang2001@yahoo.com

籍贯:山东

民族:

学位:博士

电话:020-85228481

简介:

药物研究的第一步是发现有生物活性的化合物,然后是研究这些化合物的作用机理和药理活性。王玉强实验室目前主要从事抗细菌和病毒药物、治疗糖尿病、心血管疾病药物如心肌缺血、神经退行性疾病如老年痴呆和帕金森等疾病药物的设计、化学合成、药理活性与作用机理的研究。

       王玉强教授从事DNA-minor groove binding 药物CC-1065衍生物的研究多年, 他的实验室合成了100多个CC-1065衍生物, 其中的YW-053是目前已知抗癌活性最强的少数化合物之一,其体外抗癌活性比临床应用的抗癌药物阿霉素强一百万倍 (J. Amer. Chem. Soc. 117, 8917, 1995)。
       王玉强教授在美国首次GMP合成治疗老年痴呆药物 memantine,作为核心成员,其团队在美国将memantine 成功开发。Memantine 2003年先后在欧美上市,2011年在日本上市,2013年在中国上市。Memantine 2007年的销售额达10亿美元, 正式成为“重磅炸弹”级药物。
       王玉强实验室近年开展了对中药有效成份分子结构进行系统的化学修饰的工作。在中药穿心莲、川芎及丹参有效成份的结构修饰方面已卓有成效,发现了比天然产物疗效更高,毒性更低的新化合物。其中具有独特作用机理和良好治疗效果的治疗缺血性脑中风新药已完成临床前研究。
       王玉强教授1981年毕业于山东师范大学化学系, 获学士学位;1987年获美国University of Texas Health Science Center at Houston and M. D. Anderson Cancer Center博士学位。 随后进入美国耶鲁大学 (Yale) 医学院和加拿大阿尔伯特大学 (University of Alberta) 做博士后研究。九十年代初进入美国加州硅谷的生物医药公司从事药物的研究与开发,2005年回国任暨南大学教授,药学院院长,现任暨南大学新药研究所所长,博士生导师。2010年获广州经济技术开发区科技领军人才称号,2011年入选国家 “千人计划”专家。

 

代表性论文
1. Farquhar, D.; Wang, Y. Novel antitumor organophosphates. The Cancer Bulletin Vol. 37, No.4. 167, 1985.
2.Beran, M.; Andersson, B. S.; Wang, Y.; McCredie, K. B.; Farquhar, D. The effects of acetalaldophosphamide, a novel stable aldophosphamide analogue, on normal hu-man and leukemic progenitor cells in vitro: Implications for use in bone marrow purg-ing. Cancer Res. 48, 339, 1988.
3.Andersson, B. S.; Wang, Y.; Farquhar, D. Stable in vitro active aldophosphamide acetals for bone marrow purging. Autologous Bone Marrow Transplantation, in pro-ceedings of the fourth international symposium. 1989.
4.Andersson, B. S.; Wang, Y.; McCredie, K. B.; Farquhar, D. Suitability of a new stable acetal analogue of aldoifosphamide for purging leukemic cells from human bon-e marrow. Leukemia 6, 435, 1990.
5.Wang, Y.; Farquhar, D. Aldophosphamide acetal diacetate and structural analogu-es: synthesis and cytotoxicity studies. J. Med. Chem. 34, 197, 1991.
6.Wang, Y.; Liu, M. C.; Lin, T. S.; Sartorelli, A. C. Synthesis and biological evaluat-ion of novel antitumor 3- and 5-hydroxy-4-methyl-2-formylpyridine thiosemicarba-zones and their iron-chelates. J. Med. Chem. 35, 3667, 1992.
7.Wang, Y.; Lown, J. L. An alternative method for synthesis of the CC-1065 pharm-acophore, 1,2,7,7a-tetrahydrocyclopropa[1,2-c]indol-4-one (CI). Heterocycl-es 36, 1399, 1993.
8.Wang, Y.; Gupta, R.; Huang, L.; Lown, J. W. Synthesis and antitumor activity of CC-1065 functional analogues possessing different electron-withdrawing substitue-nts and leaving groups. J. Med. Chem. 36, 4172, 1993.
9.Wang, Y.; Huang, L.; Wright, S. C.; Larrick, J. W. Synthesis and antitumor activ-ity studies of doxorubicin and DNA-minor groove binding oligopeptide conjuga-tes. Gene 149, 63, 1994.
10.Fregeau, N. L.; Wang, Y.; Pon, R, T.; Wylie, W. A.; Lown, J. W. Characterization of a CPI-Lexitropsin Conjugate: Oligonucleotide covalent complex by 1H NMR and re-strained molecular dynamics simulation. J. Amer. Chem. Soc. 117, 8917, 1995.
11.Wang, Y.; Gupta, R.; Huang, L.; Luo, W.; Lown, J. W. Design, synthesis, cyto-toxic properties and preliminary DNA sequencing evaluation of CPI-N-methy-lpyrrole hybrids. Enhancing effect of a trans double bond linker and role of the terminal amide functionality on cytotoxic potency. Anti-Cancer Drug Design 11, 15, 1996.
12.Wright, S. C.; Schellenberger, U.; Wang, H.; Wang, Y.; Kinder, D. H. Chemother-apeutic drug activation of the AP24 protease in apoptosis: Requirement for caspase 3-like proteases. Biochem. Biophys. Res. Commun. 245, 797, 1998.
13.Wang, Y.; Yuan, H.; Ye, W.; Wang, H.; Wright, S. C.; Larrick, J. W. Synthesis and pre-liminary biological evaluations of CC-1065 analogs: effects of different link-ers and terminal amides on biological activity. J. Med. Chem. 43, 1541. 2000.
14.Wang, Y.; Yuan, H.; Wright, S. C.; Wang, H.; Larrick, J. W. Synthesis and pre-liminary cytotoxicity study of a cephalosporin-CC-1065 analogue. BMC Chemical Biology 1, 4, 2001.
15.Wang, Y.; Yuan, H.; Wright, S. C.; Wang, H.; Larrick, J. W. Synthesis and cyto-toxicity of a biotinylated CC-1065 analogue. BMC Chemical Biology 2, 1. 2002.
16.Wang, Y.; Wright, S. C.; Larrick, J. W. Synthesis and cytotoxicity of nitrogen mustard derivatives of distamycin A. Bioorg. Med. Chem. Lett. 13, 461, 2003.
17.Wang, Y.; Ye, W.; Li, L.; Tian, Z.; Jiang, W.; Wang, H.; Wright, S. C.; Larrick, J. W. CC-1065 analogues bearing different DNA-binding subunits: synthesis, antitumor activity and preliminary toxicity study. J. Med. Chem. 46, 634, 2003.
18.Wang, Y.; Yuan, H.; Wang, H.; Wright, S. C.; Larrick, J. W. Synthesis and pre-liminary cytotoxicity study of glucuronide derivatives of CC-1065 analogues. Bioorg. Med. Chem. 11, 1569, 2003.
19.Wang, X.; Wang, Y.; Zheng, C. Isolation and purification of honokiol and magno-lol from Cortex Magnoliae Officinalis by high-speed counter-current chromatogra-phy. J. Chromatography A., 1036, 171, 2004.
20.Wang, X.; Wang, Y.; Yuan, J.; Sun, Q.; Liu, J.; Zheng, C. An efficient new me-thod for extraction, separation and purification of psoralen and isopsoralen from Fructus Psoraleae by supercritical fluid extraction and high-speed counter-current chromatography. J. Chromatography A, 1055, 135, 2004.
21.Wang, Y.; Li, L.; Jiang, W.; Larrick, J. W. Synthesis and evaluation of a DHA and 10-hydroxcamptothecin conjugate. Bioorg. Med. Chem. 13, 5592–5599, 2005.
22.Wang, Y.; Li, L.; Jiang, W.; Yang, Z.; Zhang, Z. Synthesis and preliminary anti-tumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg. Med. Chem. Lett. 16, 2974–2977,2006.
23.Wang, Y.; Li, L.; Tian, Z.; Jiang, W.; Larrick, J. W. Synthesis and antitumor act-ivity of CBI-bearing ester and carbamate prodrugs of CC-1065 analogue. Bioorg. Med. Chem. 14, 7854–7861, 2006.
24.Wang, Y.; Eu, J.; Washburn, M.; Gong, T.; Chen, H. S. V.; Larrick, J. W.; Lipton, S. A.; Stamler, J, S.; Went, G. T.; Porter, S. The Pharmacology of Aminoadamantane nitrates. Curr. Alzheimer Res. 3, 201–204, 2006.
25.Wang, Y., Yang, Z.; Wright, S. C.; Larrick, J. W. Synthesis and preliminary anti-tumor activity of distamycin nitrogen mustards. Lett. Drug Design and Discov. 4, 37–39, 2007.
26.Suo, X. B.; Zhang, H.; Wang, Y. HPLC determination of andrographolide in rat whole blood: study on the pharmacokinetics of andrographolide incorporated in lipo-somes and tablets.
Biomed Chromatogr. 21, 730–734, 2007.
27.Suo, X. B.; Deng, Y. J.; Zhang, H.; Wang, Y. Degradation kinetics of waterinsol-uble lauroyl-indapamide in aqueous solutions: prediction of the stabilities of the drug in liposomes. Arch Pharm Res. 30, 876–883, 2007.
28.Wang, Y.; Jiang, J.; Jiang, X.; Cai, S.; Han, H.; Li, L.; Tian, T.; Jiang, W.; Zhang, Z.; Xiao, Y.; Wei Wright, S. C.; Larrick, J. W. Synthesis and antitumor activ-ity eva-luations of albumin-binding prodrugs of CC-1065 analogue. Bioorg. Med. Chem. 16, 6552–6559, 2008.
29.Sun, Y.; Jiang, J.; Zhang, Z.; Yu, P.; Wang, L.; Xu, C.; Liu, W.; Wang, Y. Anti-oxidative and thrombolytic TMP nitrone for treatment of ischemic stroke. Bioorg. Med. Chem. 16, 8868–8874, 2008.
30.Chen, W-M.; Cheng, C.; Li, B-Z.; Ho, T-L.; Cai, Z-S.; Wang, Y.; Sun, P-H. Py-ridine-4-thiol and amphoteric analogs: novel Pprotection of aryl bromides in strong alkali. Helvetica Chimica Acta. 91, 2062–2068, 2008.
31.Guo, J-L.; Li, B-Z.; Chen, W-M.; Sun, P-H.; Wang, Y. Synthesis of substituted 1H-pyrrol-2(5H)-ones and 2(5H)-furanones as inhibitors of P. aeruginosa biofilm. Lett. Drug Design and Discov. 6, 107–113, 2009.
32.Jiang, X.; Yu, P.; Jiang, J.; Zhang, Z.; Wang, Z.; Yang, Z.; Tian, Z.; Wright, S. C.; Larrick, J. W.; Wang, Y. Synthesis and evaluation of antibacterial activities of andrographolide analogues. Eur. J. Med. Chem. 44, 2936–2943, 2009.
33.Chen, J-X.; Xue, H-J.; Ye, W-C.; Fang, B-H., Liu, Y-H., Yuan, S-H., Yu, P.; Wang, Y. Activity of andrographolide and its derivatives against influenza virus in vivo and in vitro. Biol. Pharm. Bull. 32, 1385–1391, 2009.
34.Zhang, Z.; Jiang, J.; Pei, Y.; Zeng, X.; Wang, Z.; Larrick, J. W.; Wang, Y. Hyp-oglycemic and beta cell protective andrographolide analogue for diabetes treat-ment. J. Translational Med. 7:62, 2009.
35.Xu, J.; Huang, S.; Luo, H.; Li, G.; Bao, J.; Cai, S.; Wang, Y. QSAR studies on andrographolide derivatives as α-glucosidase inhibitors. Int. J. Mol. Sci. 11, 880–895, 2010.
36.Wang, Z.; Yu, P.; Zhang, G.; Xu, L.; Wang, D.; Wang, L.; Zeng, X.; Wang, Y. Design, synthesis and antibacterial activity of novel andrographolide derivatives. Bioo-rg. Med. Chem. 18, 4269–4274, 2010.
37.Sun, H.; Xu, L.; Yu, P.; Jiang, J.; Zhang, G.; Wang, Y. Synthesis and preliminary evaluation of neuroprotection of celastrol analogues in PC12 cells. Bioorg. Med. Che-m. Lett. 20, 3844–3847, 2010.
38.Zhang, Z.; Li, S.; Jiang, J.; Yu, P.; Liang, J.; Wang, Y. Preventive effects of Flos puerariae lobatae water extract and its active ingredient puerarin in acute and chr-onic alcohol treated rat and mice model. Chinese Med. 5:36, 2010.
39.Xu, J.; Lu, Y.; Luo, H.; Huang, S.; Bao, J.; Cai, S.; Wang Y. Homology modeling of α-glucosidase and its interactions with andrograpolide derivatives. Lett. Drug Desi-gn and Discov. 8, 440–451, 2011.
40.Chen, H.; Li, S.; Wu, J.; Jiang, J.; Wang, Y. Pharmacokinetic study of a novel st-roke therapeutic, 2-[[(1,1-dimethylethyl)oxidoimino]methyl]-3,5,6-trimethy-lpyrazine, by a simple HPLC-UV method in rats. Eur. J. Drug. Metab. Ph. 36, 95–101, 2011.
41.Zeng, X.; Liu, X.; Liang, H.; Bian J.; Pei, G.; Dai, H.; Polyak, S. W.; Song, F.; Ma, L.; Wang, Y.; Zhang, Z. Synergistic effect of AL-1 and various antibiotics on the fo-rmation of biofilms and production ofexopolysaccharide and pyocyanin by Pseu-domonas aeruginosa. Antimicrob. Agents Chemother. 55, 3015–3017, 2011.
42.Cui, Q.; Zhang, G.; Yu, P.; Wang, Y.Synthesis and preliminary evalution of anti-HIV agent AZT produt .Yao Xue Xue Bao. 46, 1015–1018, 2011.
43.Lu, X.; Wan, S.; Jiang, J.; Jiang, X.; Yang, W.; Yu, P.; Xu, L.; Zhang, Z.; Zhang, G.; , Zaijun Z.; Shan, L.; Wang, Y. Synthesis and biological evaluations of novel apocynin analogues. Eur. J. Med. Chem. 46, 2691–2698. 2011.
44.Cui, Q.; Zhang, G.; Yu, P.; Wang, Y. Synthesis and preliminary evaluation of an-tiHIV agent AZT prodrug. Acta Pharmaceutica Sinica, 46, 1015–1018, 2011.
45.Yao, H.; Li, S.; Yu, P.; Tang, X.; Jiang, J.; Wang, Y. Reaction characteristics of andrographolide and its analogue AL-1with GSH as a simple chemical simulation of NF-κB Inhibition. Molecules 17, 728–739, 2011.
46.Sun, Y.; Yu.; Zhang, G.; Wang, L.; Zhong, H.; Zhai, Z.; Wang, L.; Wang, Y. Therapeutic effects of tetramethylpyrazine nitrone in rat ischemic stroke models. J. Neurosci. Res. 90, 1662–1669, 2012.
47.Sun, Y.; Zhang, G.; Zhang, Z.; Yu, P.; Zhong, H.; Du, J.; Wang, Y. Novel multi-functional nitrones for treatment of ischemic stroke. Bioorg. Med. Chem. 20, 3939–3945, 2012.
48.Yu, P.; Xia, L.; Zhao, J.; Zhang, G.; Zhang, Z,; Lang, M.; Wang, Y. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs. Biol. Pharm. Bull. 35, 1295–1299, 2012.
49.Ma, Li.; Liu, X.; Liang, H.; Che, Y.; Dai, H.; Yu, K.; Liu, M.; Ma, L.; Yang, C-H.; Song, F.; Wang, Y.; Zhang, L. Molecular targets of 14-alpha-lipoyl andrographolide on quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56, 6088–6094, 2012.
50.Cui, G.; Hung, M.; Shan, L.; Lei, S.; Choi, I.; Zhang, Z.; Hoi, M. P.; Yu, P.; Wang, Y.; Lee, S. M. A novel danshensu derivative confers cardioprotection via PI3K/Akt and Nrf2 pathways. Intl. J. Cardio. 168, 1349–1359, 2013.
51.Zhu, Y.; Yu, G.; Zhang, Y.; Xu, Z.; Wang, Y.; Yan, G.;, He, Q. A novel androgra-pholide derivative AL-1 exerts its cytotoxicity on K562 cells through a ROS-dependent mechanism. Proteomics, 13,169–178, 2013.
52.Cui, Q.; Shan, L.; Zhu, H.; Yu, P.; Wang, Y. Synthesis and preliminary evalu-ation of Danshensu derivatives modified at hydroxyl group. J. Intl. Pharm. Res. 40, 795–800, 2013.
53.Yan, G.; Zhou, H.; Wang, Y.; Zhong, Y.; Tan, Z.; Wang, Y.; He, Q. Protective effects of andrographolide analogue AL-1 on ROS-induced RIN-m β cell death by inducing ROS generation. PLoS One, 8(6):e63656. doi: 10.1371, 2013.
54.Talantovaa, M.; Sanz-Blascoa, S.; Zhang. X.; Xia, P.; Waseem Akhtara, M.; Ok-amotoa, S.; Dziewczapolskib, G.; Nakamuraa, T.; Gang, C.; Pratta, A. E.; Kanga, Y-J.; Tua, S.; Molokanovaa, E.; McKerchera, S. R.; Hiresd, A. A.; Sasone, H.; Sto-ufferf, D. G.; Buczynskif, M. W.; Solomong, J.; Michaelc, S.; Powersg, E. T.; Kell-yg, J. W.; Robertsj, A.; Tonga, G.; Fang-Newmeyera, T.; Parkera, J.; Hollanda, E. A.; Zhang, D.; Nakanishia, N.; Chen, H-S, V.; Woloskere, H.; Wang, Y.; Parsonsf, L. H.; Ambasudhana,R.; Masliahc, E.; Heinemannb, S. F.; Pi?a-Crespoa, J. C.; Lipton, S. A. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activa-tion, and synaptic loss. PNAS, 110, E2518–2527, 2013.
55.Xu, D.; Duan, H.; Du, J.; Zhang, Z.; Cui, W.; Wang, L.; Sun, Y.; Lang, M.; Hoi, P. M.; Han, Y.; Wang, Y.; Lee, S. M. The novel tetramethylpyrazine bis-nitrone (TN-2) protects against MPTP/MPP+-induced neurotoxicity via inhibition of mitochondrial de-pendent apoptosis. J. Neuroimmun. Pharmacol. 2013 (advance online DOI 10.1007/s11481-013-9514-0).
56.Guo, B.; Xu, D.; Duan, H.; Du, J.; Zhang, Z.; Lee, S. M.; Wang, Y. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson’s dis-ease in vitro and in vivo. Biol. Pharm. Bull. 37, 274–285, 2014.
57.Cui, W.; Zhang, Z.; Hu, S.; Mak, S.; Xu, D.; Choi, C.; Wang, Y.; Tsim, K.; Lee, M.; Rong, J.; Han, Y. Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction. CNS Neurosci. Ther. 2014 Jan 7. doi: 10.1111/cns.12203.
58.Sun, Y.; Liao, K.; Li, S.; Zhang, Z.; Yu, P.; Wang, Y. Pharmacokinetic analysis of bis-nitrone tetramethylpyrazine (TN-2) in rats and its protein binding in vitro. Lett. Drug Design and Discov. 2014 (advance online).
59.Lang, M.; Yan, R.; Wang, Y.; Yu, P. A selective O- and N-acylation protocol for carbamyl chloride. Chin. J. Org. Chem. 2014 (advance online).
60.Cui, Q.; Chen, Y.; Zhang, M.; Shan, L.; Sun, Y.; Yu, P.; Zhang, G.; Wang, D.; Zhao, Z.; Xu, Q.; Xu, B.; Wang, Y. Design, synthesis and preliminary cardioprote-ctive effect evaluation of Danshensu derivatives. Chem. Biol. & Drug Des. 2014 (advance online).
61.Li, S.; Shan, L.; Zhang, Z.; Li, W.; Liao, K.; Li, S.; Yu, P.; Wang, Y. Pharma-cokinetic and metabolism studies of ADTM, a novel Danshensu derivative confers cardioprotection by HPLC-UV and LC-MS/MS. J. Chromatogr. Sci. 2014 (advance online).
62.Xu, L.; Li, Y.; Wan, S.; Wang, Y.; Yu, P. Apocynin nitrone protects rats from LPS-mediated acute lung injury via inhibition of NADPH oxidase. Intl. Immunophar-macol. 2014 (advance online).
63.Du, E.; Liang, Z.; Xu, L.; Sun, S.; Zhang, G.; Yu, P.; Wang, Y. Synthesis and preliminary biologic activity evaluation of nitric oxide-releasing andrographolide ana-logues. Chem Pharma Bull. 2014 (advance online).
64.Zhang, Z.; Lai, D.; Wang, L.; Pei, Y.; Zhu, L.; Guo, B.; Xu, L.; Sun, Y.; Xu, L.; Zhou, L.; Sun, Y.; Lee, S-M.; Wang, Y. Neuroprotective effects of the androgra-pholide analogue AL-1 in the MPP+/MPTP-induced Parkinson’s disease model in vitro and in mice. Pharmacol. Biochem. Be. 2014 (advance online).
电话:(020) 8522-8481; Email: yuqiangwang2001@yahoo.com

 

我要纠正本页内容(发邮件到:datacenter@jnu.edu.cn,此为学校办公邮箱请勿发私人邮件)

  • 更新日期:2017年3月28日